Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPIRE: Cemiplimab Monotherapy or Combinations in Colorectal Cancer With Minimal Residual Disease
NCT07058012Phase 2Recruiting
- Sponsor
- NSABP Foundation
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab, fianlimab, dalmitamig in colorectal cancer (CRC), sponsored by NSABP Foundation. Started Apr 2026; status: recruiting.
02
Drugs
cemiplimabfianlimabdalmitamig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07058012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058012.